search
Back to results

The Causal Connection Between Sng and Muscle Acidosis

Primary Purpose

Muscle Acidosis

Status
Unknown status
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Phosphate Buffer Solution
Sponsored by
Taipei Medical University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Muscle Acidosis focused on measuring sngceptin, soreness, muscle acidosis

Eligibility Criteria

20 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. The subject ages ranges from 20-45 years old.
  2. The subject has no chronic pain symptoms or complaint in last 6 months.
  3. The subject is subjectively able to discriminate sng and pain.
  4. The subject has no history of major diseases that required treatment or currently being under treatment.
  5. Gender: men and women half
  6. The used hand of subject is the right hand.
  7. The educational level of subject is more than 9 years (graduated from junior high school)
  8. The subject didn't have physical and mental illness
  9. The subject didn't take prescribed medicine.
  10. The VAS questionnaire must be 0 point both of low back "pain" and low back "soreness" assessment.
  11. The subject who can fill the informed consent after understanding the purpose and medical help of this trial.

Exclusion Criteria:

  1. The subject has: Neuropathic pain due to causes other than that specified in the inclusion criteria (e.g., post-herpetic neuralgia; painful diabetic neuropathy; mononeuritis multiplex; central poststroke pain; failed back surgery in relation to the presenting episode of radiculopathy; spinal abscess, infection, hematoma, or malignancy; phantom limb pain; peripheral neuropathy due to alcoholism, malignancy, human immunodeficiency virus [HIV], syphilis; drug abuse; vitamin B12 deficiency; hypothyroidism; liver disease; toxic exposure). Pain that is associated with a substantial somatic pain component (e.g., non-neuropathic/musculoskeletal pain in lower limbs or other parts of the body apart from the back) or more than one cause or potential cause for pain symptoms.Any painful concurrent rheumatic disease such as, but not limited to, fibromyalgia, rheumatoid arthritis, or significant osteoarthritis.
  2. The subject is unable to reliably delineate or assess his or her own pain by anatomical location/distribution (e.g., the subject cannot reliably tell the difference between his or her back pain and lower limb pain and cannot rate the intensity of each separately).
  3. The subject has undergone lumbar spine surgery within the last 6 months or has received treatment with epidural injections, nerve blocks, or acupuncture for lower skin electrical resistance within 4 weeks before screening.
  4. The subject had a malignancy according to his/her report.
  5. The subject had allergic to lidocaine or monobasic sodium phosphate and dibasic sodium phosphate
  6. The subject has had a positive test for HIV antibody or a history of HIV according to his/her report.
  7. The subject has had a positive test for hepatitis B surface antigen or hepatitis C antibody according to his/her report.
  8. The subject has a history of alcohol or narcotic substance abuse according to his/her report.
  9. The subject is female and is pregnant or breastfeeding at the time of the screening visit or plans to become pregnant during the study period.
  10. The subject cannot perform brain MRI scanning who had metal implants of head (such as fixed dentures, metal bone plate, vascular clamp, vascular embolization treatment coil, deep brain stimulator, artificial electronic ear, etc.), implants of head which affecting the image quality (such as the ventricle peritoneal catheter, etc.), implantation of permanent heart rate regulator, etc.
  11. The subject has suffered from claustrophobia.
  12. The subject has a history of spinal surgery.
  13. The VAS questionnaire not be 0 point either low back "pain" or low back "soreness" assessment.
  14. The subject has mental comorbidity (such as depression, panic disorder, etc)
  15. The subject has suffered from brain disease and had brain surgery.
  16. The subject has taken prescribed medicine which can affect specific function of brian (such as sleeping pills, tranquilizer, etc.).
  17. The subject has mental retardation.
  18. The educational level of subject is less than 9 years.
  19. The subject who under 20 years old or older than 45 years old, who is unable to understand the purpose of this trial and fill the informed consent.

Sites / Locations

  • Taipei Medical University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Acidic phosphate buffer solution

Neutral phosphate buffer solution

Arm Description

pH5.2 phosphate buffer solution

pH7.4 phosphate buffer solution

Outcomes

Primary Outcome Measures

Brain functional magnetic resonance imaging
All images will be acquired on a 3 Tesla MRI system (MAGNETOM Prisma, Siemens, Erlangen, Germany) with a 20-channel head coil. To obtain an anatomical reference, high-resolution T1-weighted imaging was performed using a 3D magnetization-prepared rapid gradient echo (MPRAGE) sequence: repetition time (TR)/echo time (TE) = 2000 ms/3 ms, flip angle = 9°, field of view (FOV) = 256 × 192 × 208 mm3, acquisition matrix = 256 × 192 × 208, resulting in isotropic spatial resolution of 1 mm3. The task fMRI will be performed using an echo planar imaging (EPI) sequence with a twice-refocused balanced echo. The imaging parameters are: TR/TE = 2000/20 ms, slice thickness = 3.5 mm, 80 × 80 acquisition matrix, FOV = 200 × 200 mm, and in-plane spatial resolution = 3.0 mm x 3.0 mm.

Secondary Outcome Measures

The visual analog scale (VAS) of "sng" in the legs
The subject will be asked for sng VAS before infusion and immediately after infusion. Scale range 0 to 10 (1)0: No Sng (2)1-3: Mild Sng (3)4-6: Moderate Sng (4)7-9: Severe Sng (5)10: Worst Sng imaginable
Muscle pressure pain threshold
Muscle pressure pain threshold on bilateral tibialis anterior muscles will be measured by algometer.

Full Information

First Posted
July 23, 2019
Last Updated
October 6, 2020
Sponsor
Taipei Medical University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04049253
Brief Title
The Causal Connection Between Sng and Muscle Acidosis
Official Title
The Causal Connection Between Sng and Muscle Acidosis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 11, 2019 (Actual)
Primary Completion Date
July 31, 2021 (Anticipated)
Study Completion Date
January 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Taipei Medical University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This proposed study suggests that peripheral tissue acidosis sensed by the somatosensory system (sngceptin) would evoke the sng perception in the brain. This hypothesis is based on investigators preliminary data that the peripheral muscle acidosis will evoked the central sng perception. This proposed study also identify the detection of brain activation areas related to the peripheral muscle acidosis. Investigators will know specific brain areas related to sng perception evoked by the peripheral muscle acidosis and, accordingly, a novel mechanism and potential treatment for sng would be developed in this proposed study.
Detailed Description
Sng is a prominent complaint in Taiwanese people with low back pain. "Sng" is created to represent this Taiwanese word. Based on investigators preliminary data, sng was one of the most common complaints in patients with chronic low back pain (CLBP) and also one of the most common indication for lumbar spine operations. Back sng is not adequately relieved by pain-killers or even by the lumbar spine operations. By using functional magnetic resonance imaging and questionnaires, the investigators preliminary study demonstrated that sng is different from pain in the level of brain perception and the level of subjective concept. It is very likely that sng has its own unique nerve pathway other than pain. The subjective feeling of sng is very similar to sour in taste, so it is likely that acidosis may be involved in the process of sng sensation, especially in the muscle. Delayed onset muscle soreness is a well-known example, and the soreness is dependent on the proton-sensing neurons. Indeed, substantial evidences showed that up to 80% muscle afferents are acid-sensitive but not nociceptors. Therefore, the investigators propose that sng is the perception in the brain when the tissue acidosis is sensed by the somatosensory system, and "sng-ception" is created to indicate the sensation of tissue acidosis. However, the causal connection between the peripheral sngception and the central brain perception of sng is not established. The objective of this proposal is to establish the causal connection between peripheral muscle acidosis and the central brain sng perception. The investigators central hypothesis is that acidosis-evoked sensation in the muscles will cause a central sng perception in the brain. This hypothesis is based on investigators previous studies that showed sng is different from pain in terms of subjective responses, brain activation areas and clinical impacts. To achieve this goal, two specific aims will be pursued 1. to determine if an acid solution will evokes sng response, and, 2. to detect the brain activation area of sng evoked by an acid solution in functional magnetic resonance imaging. Successful establishment of the casual connection between the peripheral muscle acidosis and the central brain sng perception will lead to a more comprehensive understanding of sng mechanism and the potential medication development.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Acidosis
Keywords
sngceptin, soreness, muscle acidosis

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
52 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Acidic phosphate buffer solution
Arm Type
Experimental
Arm Description
pH5.2 phosphate buffer solution
Arm Title
Neutral phosphate buffer solution
Arm Type
Placebo Comparator
Arm Description
pH7.4 phosphate buffer solution
Intervention Type
Drug
Intervention Name(s)
Phosphate Buffer Solution
Other Intervention Name(s)
Sodium phosphate solution, Phosphate buffered saline
Intervention Description
Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
Primary Outcome Measure Information:
Title
Brain functional magnetic resonance imaging
Description
All images will be acquired on a 3 Tesla MRI system (MAGNETOM Prisma, Siemens, Erlangen, Germany) with a 20-channel head coil. To obtain an anatomical reference, high-resolution T1-weighted imaging was performed using a 3D magnetization-prepared rapid gradient echo (MPRAGE) sequence: repetition time (TR)/echo time (TE) = 2000 ms/3 ms, flip angle = 9°, field of view (FOV) = 256 × 192 × 208 mm3, acquisition matrix = 256 × 192 × 208, resulting in isotropic spatial resolution of 1 mm3. The task fMRI will be performed using an echo planar imaging (EPI) sequence with a twice-refocused balanced echo. The imaging parameters are: TR/TE = 2000/20 ms, slice thickness = 3.5 mm, 80 × 80 acquisition matrix, FOV = 200 × 200 mm, and in-plane spatial resolution = 3.0 mm x 3.0 mm.
Time Frame
The whole procedures will be done within 50 minutes. Before the injection, the subject will receive anatomical MRI scan (10 minutes) and baseline fMRI scan (10 minutes) After that, the acid or pH 7.4 PBS will be given into the midpoint of the left tibial
Secondary Outcome Measure Information:
Title
The visual analog scale (VAS) of "sng" in the legs
Description
The subject will be asked for sng VAS before infusion and immediately after infusion. Scale range 0 to 10 (1)0: No Sng (2)1-3: Mild Sng (3)4-6: Moderate Sng (4)7-9: Severe Sng (5)10: Worst Sng imaginable
Time Frame
Through fMRI completion an average of 6 months
Title
Muscle pressure pain threshold
Description
Muscle pressure pain threshold on bilateral tibialis anterior muscles will be measured by algometer.
Time Frame
Through fMRI completion an average of 1 week
Other Pre-specified Outcome Measures:
Title
36-Item Short Form Health Survey (RAND)
Description
Investigator will evaluate the subject life quality and activity of daily life by 36-Item Short Form Health Survey (RAND) Consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time Frame
Up to 6 months before signing the informed consent form
Title
The visual analog scale (VAS) of "sng" in the back
Description
The subject will be asked for sng VAS before infusion and immediately after infusion. Scale range 0 to 10 (1)0: No Sng (2)1-3: Mild Sng (3)4-6: Moderate Sng (4)7-9: Severe Sng (5)10: Worst Sng imaginable
Time Frame
Through fMRI completion an average of 6 months
Title
Oswestry disability index
Description
Investigator will evaluate the subject activity of daily life by Oswestry disability index The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100) (1)0 -20: Minimal disability (2)21-40: Moderate Disability (3)41-60: Severe Disability (4)61-80: Crippling back pain (5)81-100: These patients are either bed-bound or have an exaggeration of their symptoms
Time Frame
Up to 6 months before signing the informed consent form
Title
The Hospital Anxiety and Depression Scale
Description
Is a 14-item measure designed to assess anxiety and depression symptoms in subjects, with emphasis on reducing the impact of physical illness. Total score (Depression、Anxiety): (1)0-7 Normal (2)8-10 Borderline abnormal (borderline case) (3)11-21 Abnormal (case)
Time Frame
Up to 6 months before signing the informed consent form
Title
Edinburgh Handedness Inventory
Description
Is a measurement scale used to assess the dominance of a person's right or left hand in everyday activities, sometimes referred to as laterality. The inventory can be used by an observer assessing the person. Handedness score is calculated using this formula: 100*((Right - Left) / (Right + Left)). Pure left hander: total score=-100 Mixed left hander:-100< total score <0 Neutral: total score=0 Mixed right hander:0< total score <100 Pure left hander:total score=100
Time Frame
Up to 6 months before signing the informed consent form

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The subject ages ranges from 20-45 years old. The subject has no chronic pain symptoms or complaint in last 6 months. The subject is subjectively able to discriminate sng and pain. The subject has no history of major diseases that required treatment or currently being under treatment. Gender: men and women half The used hand of subject is the right hand. The educational level of subject is more than 9 years (graduated from junior high school) The subject didn't have physical and mental illness The subject didn't take prescribed medicine. The VAS questionnaire must be 0 point both of low back "pain" and low back "soreness" assessment. The subject who can fill the informed consent after understanding the purpose and medical help of this trial. Exclusion Criteria: The subject has: Neuropathic pain due to causes other than that specified in the inclusion criteria (e.g., post-herpetic neuralgia; painful diabetic neuropathy; mononeuritis multiplex; central poststroke pain; failed back surgery in relation to the presenting episode of radiculopathy; spinal abscess, infection, hematoma, or malignancy; phantom limb pain; peripheral neuropathy due to alcoholism, malignancy, human immunodeficiency virus [HIV], syphilis; drug abuse; vitamin B12 deficiency; hypothyroidism; liver disease; toxic exposure). Pain that is associated with a substantial somatic pain component (e.g., non-neuropathic/musculoskeletal pain in lower limbs or other parts of the body apart from the back) or more than one cause or potential cause for pain symptoms.Any painful concurrent rheumatic disease such as, but not limited to, fibromyalgia, rheumatoid arthritis, or significant osteoarthritis. The subject is unable to reliably delineate or assess his or her own pain by anatomical location/distribution (e.g., the subject cannot reliably tell the difference between his or her back pain and lower limb pain and cannot rate the intensity of each separately). The subject has undergone lumbar spine surgery within the last 6 months or has received treatment with epidural injections, nerve blocks, or acupuncture for lower skin electrical resistance within 4 weeks before screening. The subject had a malignancy according to his/her report. The subject had allergic to lidocaine or monobasic sodium phosphate and dibasic sodium phosphate The subject has had a positive test for HIV antibody or a history of HIV according to his/her report. The subject has had a positive test for hepatitis B surface antigen or hepatitis C antibody according to his/her report. The subject has a history of alcohol or narcotic substance abuse according to his/her report. The subject is female and is pregnant or breastfeeding at the time of the screening visit or plans to become pregnant during the study period. The subject cannot perform brain MRI scanning who had metal implants of head (such as fixed dentures, metal bone plate, vascular clamp, vascular embolization treatment coil, deep brain stimulator, artificial electronic ear, etc.), implants of head which affecting the image quality (such as the ventricle peritoneal catheter, etc.), implantation of permanent heart rate regulator, etc. The subject has suffered from claustrophobia. The subject has a history of spinal surgery. The VAS questionnaire not be 0 point either low back "pain" or low back "soreness" assessment. The subject has mental comorbidity (such as depression, panic disorder, etc) The subject has suffered from brain disease and had brain surgery. The subject has taken prescribed medicine which can affect specific function of brian (such as sleeping pills, tranquilizer, etc.). The subject has mental retardation. The educational level of subject is less than 9 years. The subject who under 20 years old or older than 45 years old, who is unable to understand the purpose of this trial and fill the informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiann-Her Lin, MD/PhD
Phone
+886973405133
Email
jiannher@me.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jiann-Her Lin, MD/PhD
Organizational Affiliation
Taipei Medical University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Taipei Medical University Hospital
City
Taipei City
State/Province
No.252, Wusing St., Sinyi Dist.
ZIP/Postal Code
11031
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiann-Her Lin, MD/PhD
Phone
+886973405133
Email
jiannher@me.com
First Name & Middle Initial & Last Name & Degree
Jiann-Her Lin, MD/PhD
First Name & Middle Initial & Last Name & Degree
Li-Chun Hsieh, MD/PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
8733302
Citation
Issberner U, Reeh PW, Steen KH. Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia? Neurosci Lett. 1996 Apr 26;208(3):191-4. doi: 10.1016/0304-3940(96)12576-3.
Results Reference
background
PubMed Identifier
18835099
Citation
Law LAF, Sluka KA, McMullen T, Lee J, Arendt-Nielsen L, Graven-Nielsen T. Acidic buffer induced muscle pain evokes referred pain and mechanical hyperalgesia in humans. Pain. 2008 Nov 30;140(2):254-264. doi: 10.1016/j.pain.2008.08.014. Epub 2008 Oct 2.
Results Reference
background
PubMed Identifier
30486810
Citation
Lin JH, Hung CH, Han DS, Chen ST, Lee CH, Sun WZ, Chen CC. Sensing acidosis: nociception or sngception? J Biomed Sci. 2018 Nov 29;25(1):85. doi: 10.1186/s12929-018-0486-5.
Results Reference
background
PubMed Identifier
18834667
Citation
Fujii Y, Ozaki N, Taguchi T, Mizumura K, Furukawa K, Sugiura Y. TRP channels and ASICs mediate mechanical hyperalgesia in models of inflammatory muscle pain and delayed onset muscle soreness. Pain. 2008 Nov 30;140(2):292-304. doi: 10.1016/j.pain.2008.08.013. Epub 2008 Oct 1.
Results Reference
background
PubMed Identifier
23490035
Citation
Chen CC, Wong CW. Neurosensory mechanotransduction through acid-sensing ion channels. J Cell Mol Med. 2013 Mar;17(3):337-49. doi: 10.1111/jcmm.12025. Epub 2013 Mar 14.
Results Reference
background
PubMed Identifier
24957987
Citation
Chen WN, Lee CH, Lin SH, Wong CW, Sun WH, Wood JN, Chen CC. Roles of ASIC3, TRPV1, and NaV1.8 in the transition from acute to chronic pain in a mouse model of fibromyalgia. Mol Pain. 2014 Jun 23;10:40. doi: 10.1186/1744-8069-10-40.
Results Reference
background

Learn more about this trial

The Causal Connection Between Sng and Muscle Acidosis

We'll reach out to this number within 24 hrs